124 related articles for article (PubMed ID: 11280687)
1. Changes to the Pharmaceutical Benefits Advisory Committee.
Henry DA; Birkett DJ
Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
[No Abstract] [Full Text] [Related]
2. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
Thöns M
MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
[No Abstract] [Full Text] [Related]
3. [New institute for additional drug evaluation. Do we really need another barrier?].
Schmidt K
MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
[No Abstract] [Full Text] [Related]
4. Easy ride for drug industry.
McBane M
Health Aff (Millwood); 2003; 22(4):259-60. PubMed ID: 12889775
[No Abstract] [Full Text] [Related]
5. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
Hailey D
Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
[TBL] [Abstract][Full Text] [Related]
6. [Negative would be welcome. The question is whose brain child this is].
Hakimi R
MMW Fortschr Med; 2006 Nov; 148(44):8. PubMed ID: 17632867
[No Abstract] [Full Text] [Related]
7. [Limited prescribing freedom by federal cost regulation?].
Lasek R
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
[TBL] [Abstract][Full Text] [Related]
8. [How AMOG limits the supply of diabetes drugs].
Oberhofer E
MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
[No Abstract] [Full Text] [Related]
9. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
10. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
11. [Psychopharmacological regulations. Results and commentary to the report on drug regulations 2002].
Fritze J
Nervenarzt; 2003 Mar; 74(3):301-6. PubMed ID: 12722759
[No Abstract] [Full Text] [Related]
12. [Off-label use in psychopharmacotherapy].
Fritze J; Schmauss M
Nervenarzt; 2002 Aug; 73(8):796-9. PubMed ID: 12242971
[No Abstract] [Full Text] [Related]
13. The market for pharmaceuticals.
Bergenheim K; Braun U
Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
[No Abstract] [Full Text] [Related]
14. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
15. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
16. [Pharmacists want to assume penalty].
MMW Fortschr Med; 2006 May; 148(20):55. PubMed ID: 16805194
[No Abstract] [Full Text] [Related]
17. [Drug cost saving law: Order purposefully past the penalty].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(51-52):68. PubMed ID: 17619354
[No Abstract] [Full Text] [Related]
18. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
Antoñanzas F; Gómez P
Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
[No Abstract] [Full Text] [Related]
19. The drug budget silo mentality in Europe: an overview.
Garrison L; Towse A
Value Health; 2003; 6 Suppl 1():S1-9. PubMed ID: 12846921
[No Abstract] [Full Text] [Related]
20. [European court. Drug budgets of physicians remain reduced].
MMW Fortschr Med; 2004 Mar; 146(13):57. PubMed ID: 15219133
[No Abstract] [Full Text] [Related]
[Next] [New Search]
